Savara (SVRA) EBT Margin (2013 - 2020)

Name: Savara (SVRA) EBT Margin (2013 - 2020) | Business Quant
Creator: Business Quant

Savara (SVRA) reported EBT Margin of 1354200.0% for Q4 2020, down 30732.02% on a QoQ basis from 4392.19% in Q3 2020.

Savara (SVRA) has 5 years of EBT Margin data on file, last reported at 1354200.0% in Q4 2020.

Quarterly EBT Margin changed N/A year-over-year to 1354200.0% in Q4 2020, while the trailing twelve-month figure through Mar 2022 was 4136800.0% (changed N/A YoY) and the FY2020 annual result came in at 19759.53%, changed N/A from the prior year.
EBT Margin fell to 1354200.0% in Q4 2020 per SVRA's latest filing, from 4392.19% in the prior quarter.
Across five years, EBT Margin topped out at 12738.3% in Q2 2017 and bottomed at 1354200.0% in Q4 2020.
The 3-year median for EBT Margin is 4967.9% (2017), against an average of 226544.77%.
Peak annual rise in EBT Margin reached 2182037 bps in 2016, while the deepest fall reached 2182037 bps in 2016.
Tracing SVRA's EBT Margin over 3 years: stood at 700.0% in 2016, then surged by 1920 bps to 12738.3% in 2017, then slumped by 10731 bps to 1354200.0% in 2020.
Per Business Quant, the three latest SVRA EBT Margin figures stand at 1354200.0% (Q4 2020), 4392.19% (Q3 2020), and 12738.3% (Q2 2017).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-6.40%
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	41.95%
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	23.05%
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	18.99%
10	Savara	1.30 Bn	1.30 Bn	-	-

Download Data 🔒